Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

A. S. Abeyagunawardena, D. Goldblatt, N. Andrews, R. S. Trompeter*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)


In November, 1999, all children under age 18 years in the UK were offered immunisation with the newly introduced meningococcal C conjugate vaccine (MCCV). In a cohort of 106 patients with nephrotic syndrome, there were 63 relapses during the 12 months before vaccination, and 96 during the equivalent period postvaccination (p=0.009). The relapse rate of nephrotic syndrome increased significantly after administration of MCCV. Whether to vaccinate such children needs to be carefully considered.

Original languageEnglish
Pages (from-to)449-450
Number of pages2
JournalThe Lancet
Issue number9382
Publication statusPublished - 9 Aug 2003

Bibliographical note

Funding Information:
ASA was supported by The Caring for Kids Fund (Child Health Research Appeal Trust). The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or in writing of the report.


Dive into the research topics of 'Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome'. Together they form a unique fingerprint.

Cite this